Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Purinergic Signal ; 12(3): 497-507, 2016 09.
Article in English | MEDLINE | ID: mdl-27172914

ABSTRACT

ADP and other nucleotides control ion currents in the nervous system via various P2Y receptors. In this respect, Cav2 and Kv7 channels have been investigated most frequently. The fine tuning of neuronal ion channel gating via G protein coupled receptors frequently relies on the formation of higher order protein complexes that are organized by scaffolding proteins and harbor receptors and channels together with interposed signaling components. However, ion channel complexes containing P2Y receptors have not been described. Therefore, the regulation of Cav2.2 and Kv7.2/7.3 channels via P2Y1 and P2Y12 receptors and the coordination of these ion channels and receptors in the plasma membranes of tsA 201 cells have been investigated here. ADP inhibited currents through Cav2.2 channels via both P2Y1 and P2Y12 receptors with phospholipase C and pertussis toxin-sensitive G proteins being involved, respectively. The nucleotide controlled the gating of Kv7 channels only via P2Y1 and phospholipase C. In fluorescence energy transfer assays using conventional as well as total internal reflection (TIRF) microscopy, both P2Y1 and P2Y12 receptors were found juxtaposed to Cav2.2 channels, but only P2Y1, and not P2Y12, was in close proximity to Kv7 channels. Using fluorescence recovery after photobleaching in TIRF microscopy, evidence for a physical interaction was obtained for the pair P2Y12/Cav2.2, but not for any other receptor/channel combination. These results reveal a membrane juxtaposition of P2Y receptors and ion channels in parallel with the control of neuronal ion currents by ADP. This juxtaposition may even result in apparent physical interactions between receptors and channels.


Subject(s)
Adenosine Diphosphate/metabolism , Ion Channels/metabolism , Neurons/metabolism , Receptors, Purinergic P2Y12/metabolism , Receptors, Purinergic P2Y1/metabolism , Calcium Channels, N-Type/metabolism , Cell Line , Humans , KCNQ2 Potassium Channel/metabolism , KCNQ3 Potassium Channel/metabolism , Microscopy, Confocal , Microscopy, Fluorescence , Patch-Clamp Techniques
2.
Pflugers Arch ; 466(12): 2289-303, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24668449

ABSTRACT

The slow cholinergic transmission in autonomic ganglia is known to be mediated by an inhibition of Kv7 channels via M1 muscarinic acetylcholine receptors. However, in the present experiments using primary cultures of rat superior cervical ganglion neurons, the extent of depolarisation caused by the M1 receptor agonist oxotremorine M did not correlate with the extent of Kv7 channel inhibition in the very same neuron. This observation triggered a search for additional mechanisms. As the activation of M1 receptors leads to a boost in protein kinase C (PKC) activity in sympathetic neurons, various PKC enzymes were inhibited by different means. Interference with classical PKC isoforms led to reductions in depolarisations and in noradrenaline release elicited by oxotremorine M, but left the Kv7 channel inhibition by the muscarinic agonist unchanged. M1 receptor-induced depolarisations were also altered when extra- or intracellular Cl(-) concentrations were changed, as were depolarising responses to γ-aminobutyric acid. Depolarisations and noradrenaline release triggered by oxotremorine M were reduced by the non-selective Cl(-) channel blockers 4-acetamido-4'-isothiocyanato-stilbene-2,2'-disulfonic acid and niflumic acid. Oxotremorine M induced slowly rising inward currents at negative membrane potentials that were blocked by inhibitors of Ca(2+)-activated Cl(-) and TMEM16A channels and attenuated by PKC inhibitors. These channel blockers also reduced oxotremorine M-evoked noradrenaline release. Together, these results reveal that slow cholinergic excitation of sympathetic neurons involves the activation of classical PKCs and of Ca(2+)-activated Cl(-) channels in addition to the well-known inhibition of Kv7 channels.


Subject(s)
Action Potentials , KCNQ Potassium Channels/metabolism , Neurons/metabolism , Receptor, Muscarinic M1/metabolism , Superior Cervical Ganglion/metabolism , Animals , Cells, Cultured , Chloride Channels/antagonists & inhibitors , Chlorides/metabolism , Muscarinic Agonists/pharmacology , Neurons/physiology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Rats , Rats, Sprague-Dawley , Receptor, Muscarinic M1/agonists , Superior Cervical Ganglion/cytology , Superior Cervical Ganglion/physiology
3.
J Pharmacol Exp Ther ; 348(2): 346-58, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24307198

ABSTRACT

Ibogaine is a psychoactive indole alkaloid. Its use as an antiaddictive agent has been accompanied by QT prolongation and cardiac arrhythmias, which are most likely caused by human ether a go-go-related gene (hERG) potassium channel inhibition. Therefore, we studied in detail the interaction of ibogaine with hERG channels heterologously expressed in mammalian kidney tsA-201 cells. Currents through hERG channels were blocked regardless of whether ibogaine was applied via the extracellular or intracellular solution. The extent of inhibition was determined by the relative pH values. Block occurred during activation of the channels and was not observed for resting channels. With increasing depolarizations, ibogaine block grew and developed faster. Steady-state activation and inactivation of the channel were shifted to more negative potentials. Deactivation was slowed, whereas inactivation was accelerated. Mutations in the binding site reported for other hERG channel blockers (Y652A and F656A) reduced the potency of ibogaine, whereas an inactivation-deficient double mutant (G628C/S631C) was as sensitive as wild-type channels. Molecular drug docking indicated binding within the inner cavity of the channel independently of the protonation of ibogaine. Experimental current traces were fit to a kinetic model of hERG channel gating, revealing preferential binding of ibogaine to the open and inactivated state. Taken together, these findings show that ibogaine blocks hERG channels from the cytosolic side either in its charged form alone or in company with its uncharged form and alters the currents by changing the relative contribution of channel states over time.


Subject(s)
Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Excitatory Amino Acid Antagonists/pharmacology , Hallucinogens/pharmacology , Ibogaine/pharmacology , Narcotic Antagonists/pharmacology , Nerve Tissue Proteins/antagonists & inhibitors , Amino Acid Substitution , Binding Sites/drug effects , Cell Line , Cytosol/metabolism , ERG1 Potassium Channel , Ether-A-Go-Go Potassium Channels/chemistry , Ether-A-Go-Go Potassium Channels/genetics , Ether-A-Go-Go Potassium Channels/metabolism , Excitatory Amino Acid Antagonists/adverse effects , Excitatory Amino Acid Antagonists/chemistry , Hallucinogens/adverse effects , Hallucinogens/chemistry , Humans , Hydrogen-Ion Concentration , Ibogaine/adverse effects , Ibogaine/chemistry , Ion Channel Gating/drug effects , Kinetics , Membrane Potentials/drug effects , Membrane Transport Modulators/pharmacology , Molecular Conformation , Molecular Docking Simulation , Mutant Proteins/agonists , Mutant Proteins/antagonists & inhibitors , Mutant Proteins/chemistry , Mutant Proteins/metabolism , Narcotic Antagonists/adverse effects , Narcotic Antagonists/chemistry , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...